08 Apr 2026
22m
The new CEO of Stoke Therapeutics, Ian Smith, discusses Stoke Therapeutics' Dravet syndrome therapy, which caught much attention after publishing phase 1/2 data in NEJM last month
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.